In the last trading session, 1.28 million Anavex Life Sciences Corporation (NASDAQ:AVXL) shares changed hands as the company’s beta touched 0.93. With the company’s per share price at $7.99 changed hands at -$0.27 or -3.27% during last session, the market valuation stood at $679.66M. AVXL’s last price was a discount, traded about -80.73% off its 52-week high of $14.44. The share price had its 52-week low at $3.25, which suggests the last value was 59.32% up since then.
Analysts gave the Anavex Life Sciences Corporation (AVXL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended AVXL as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Anavex Life Sciences Corporation’s EPS for the current quarter is expected to be -0.16.
Anavex Life Sciences Corporation (NASDAQ:AVXL) trade information
Instantly AVXL was in red as seen at the end of in last trading. With action -8.16%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -25.61%, with the 5-day performance at -8.16% in the red. However, in the 30-day time frame, Anavex Life Sciences Corporation (NASDAQ:AVXL) is -23.83% down.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 27.36% from its current market value. According to analyst projections, AVXL’s forecast low is 11 with 11 as the target high. To hit the forecast high, the stock’s price needs a -37.67% plunge from its current level, while the stock would need to soar -37.67% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.85%. The 2025 estimates are for Anavex Life Sciences Corporation earnings to decrease by -16.67%.
AVXL Dividends
Anavex Life Sciences Corporation is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.5154% or 4.55 million shares worth $19.19 million as of 2024-06-30.
